Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

What's In Store For GNC Holdings (GNC) This Earnings Season?

Published 02/04/2018, 10:24 PM
Updated 07/09/2023, 06:31 AM

GNC Holdings, Inc. (NYSE:GNC) is expected to report fourth-quarter 2017 results on Feb 15, before the opening bell.

Last quarter, the company posted a negative earnings surprise of 3%. Also, GNC Holdings’ trailing four-quarter average earnings miss is 16.5%.

Let’s take a look at GNC Holdings’ announcement of preliminary fourth-quarter results.

Per the announcement, GNC Holdings saw an increase in fourth-quarter same store sales for domestic company-owned stores (including GNC.com sales) of 5.7%. Also, adjusted diluted earnings per share (EPS) are expected in the range of 24-25 cents compared with 7 cents in the prior-year quarter. In the year-ago quarter, the EPS decline was led by a substantial fall in revenues.

GNC Holdings, Inc. Price and EPS Surprise

GNC Holdings, Inc. Price and EPS Surprise | GNC Holdings, Inc. Quote

Meanwhile, the Zacks Consensus Estimate for earnings is pegged at 24 cents, reflecting a 25% decline from last quarter. Further, the Zacks Consensus Estimate for revenues is pegged at $558 million, reflecting a 8.4% drop from the preceding quarter.

Other Factors at Play

Dull Prospects in the U.S. & Canada Segment

GNC Holdings' third-quarter 2017 revenues dropped 2.9% year over year. The lower sales at the U.S. & Canada and manufacturing/wholesale segments can be cited as main reasons for the disappointing performance. In the absence of any catalyst, we expect a similar trend in the fourth quarter of 2017.

The Zacks Consensus Estimate for revenues at the segment stands at $452 million, reflecting a 4.4% decline from the year-ago quarter.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

China e-commerce to Drive International Segment

Revenues at the international segment increased a whopping 19.3% in the last quarter. Revenues from international franchisees rose impressively. Solid performance in the China e-commerce platform is likely to be the key catalyst. As a result, the Zacks Consensus Estimate for revenues at the segment is pegged at $44.2 million, reflecting growth of 11.3% from the year-earlier quarter.

However, GNC Holdings has a number of competitors in the market that include large international pharmacy chains, supermarket firms and big U.S.-based companies with global operations. We expect the company to slash prices in the face of stiff competition, which in turn, might hurt margins.

Other Developments

On the bright side, the performance of One New GNC is improving gradually. PRO Access, the company’s premium loyalty offering, has enrolled nearly 585,000 members since its launch in March 2017. Apart from this, management is working on product pricing and innovation. Meanwhile, new consumer enrolment under the myGNC Rewards Program and launch of GNC storefront on Amazon (NASDAQ:AMZN) buoy optimism.

Earnings Whispers

Our proven model does not conclusively show an earnings beat for GNC Holdings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.

Zacks ESP: The Earnings ESP for GNC Holdings is 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Rank: GNC Holdings carries a Zacks Rank #3, which increases the predictive power of ESP. However, we also need to have a positive ESP to be confident of a positive earnings surprise.

Stocks to Consider

Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.

Bio-Rad Laboratories (NYSE:BIO) has an Earnings ESP of +4.45% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Myriad Genetics (NASDAQ:MYGN) has an Earnings ESP of +0.42% and a Zacks Rank #3.

Henry Schein (NASDAQ:HSIC) has an Earnings ESP of +0.09% and a Zacks Rank #3.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>



Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report

Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

GNC Holdings, Inc. (GNC): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.